NDA 210868 · Pfizer
Lorbrena
Lorlatinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jan 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Nov 2, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
59
3 Phase 3, 16 recruiting
FAERS reports
7,455
6,225 serious, 2,070 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 26, 2026.
LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. ( 1 , 2.1 )
Mechanism: Lorlatinib is a kinase inhibitor with in vitro activity against ALK and ROS1 as well as TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, and ACK. Lorlatinib demonstrated in vitro activity against multiple mutant forms of the ALK enzyme, including some mutations detected in tumors at the time of disease progression on crizotinib and other ALK inhibitors. In mice subcutaneously implanted with tumors harboring EML4 fusions with either ALK variant 1 or ALK mutations, including the G1202R and I1171T mutations detected in tumors at the time of disease progression on ALK inhibitors, administration of...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 3, 2021 Supplement 4 · Efficacy · priority review OrphanLabelLetter
- Nov 2, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
- LORBRENA · LORLATINIB 25MG · TABLET, ORAL · Prescription
- LORBRENA · LORLATINIB 100MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lorlatinib" as an intervention, any sponsor and status, largest first.
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
Nuvalent Inc.Industry
NCT05384626 · 840 participants (planned) · Start Jun 9, 2022 · Primary completion Dec 2027
Drug: Neladalkib (NVL-655); Midazolam and 2 more · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Orange, California; Sacramento, California; Stanford, California · 74 sites in all
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Pivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03126916 · 750 participants (planned) · Start May 14, 2018 · Primary completion Sep 30, 2030
Drug: Busulfan; Carboplatin and 13 more · For: Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 164 sites in all
PfizerPfizer (PFE)
NCT01970865 · 364 participants · Start Jan 8, 2014 · Primary completion Mar 15, 2017
Drug: PF-06463922; Crizotinib · For: ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Orange, California · 77 sites in all
- A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT03052608 · 296 participants · Start Apr 27, 2017 · Primary completion Mar 20, 2020
Drug: Lorlatinib; Crizotinib · For: Carcinoma, Non-Small-Cell Lung
Sites: Altamonte Springs, Florida; Brandon, Florida; Clearwater, Florida · 166 sites in all
TRIANA Biomedicines, Inc.Industry
NCT07491497 · 160 participants (planned) · Start Mar 11, 2026 · Primary completion May 31, 2029
Drug: TRI-611 · For: ALK-positive NSCLC; ALK-Positive Lung Cancer; ALK-positive Non-small Cell Lung Cancer
Sites: San Francisco, California; Aurora, Colorado; Boston, Massachusetts · 20 sites in all
- Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLCPivotal-lookingNot yet recruiting
Guangdong Association of Clinical TrialsAcademic, hospital or other
NCT07750704 · 153 participants (planned) · Start Sep 2026 · Primary completion Sep 2029
Drug: Lorlatinib; sacituzumab tirumotecan plus lorlatinib · For: ALK Positive Non-small Cell Lung Cancer
Sites: Guangzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death1,486
- neoplasm progression620
- off label use457
- hallucination447
- weight increased433
- blood cholesterol increased381
- dyspnoea293
- malignant neoplasm progression285
- oedema280
- fatigue273
- oedema peripheral270
- peripheral swelling229
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 56 |
| 2019 | 552 |
| 2020 | 508 |
| 2021 | 595 |
| 2022 | 692 |
| 2023 | 918 |
| 2024 | 1,225 |
| 2025 | 1,565 |
| 2026 | 1,336 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Jun 15, 2026
Lorbrena, Tablet, 25 mg; 120 tablets bottle with a child-resistant closure (NDC 0069-0227-03). Supply expected to exhaust 6/30/2026; NDC 0069-0227-01 25 mg; 30 tablets bottle with a child-resistant closure will continue...
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lorbrena (Lorlatinib)
2024 spending
$117M
Beneficiaries
868
5,896 claims
Per beneficiary
$134,486
$485.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $31,446,261 |
| 2021 | $42,609,600 |
| 2022 | $61,934,706 |
| 2023 | $75,625,415 |
| 2024 | $116,734,265 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
Solomon BJ, Liu G, Felip E, et al. · J Clin Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.
Shaw AT, Solomon BJ, Felip E, et al. · Ann Oncol 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Goldsmith KC, Park JR, Kayser K, et al. · Nat Med 2023 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ, Bauer TM, Mok TSK, et al. · Lancet Respir Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).
Ou SH, Kilvert H, Candlish J, et al. · Lung Cancer 2024 · Systematic Review, Comparative Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.